Elektrofi - Crunchbase Company Profile & Funding

Q: Who invested in Elektrofi?

Elektrofi has 20 investors including Novo Holdings And Braidwell.

Q: When was the last funding round for Elektrofi?

Elektrofi closed its last funding round on obfuscated from a Series C round.

Q: How much funding has Elektrofi raised to date?

Elektrofi has raised obfuscated.

Overview

Elektrofi

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Elektrofi

CB Rank

22728

Elektrofi develops hyper concentration microparticle technology for subcutaneous biologic medicine delivery.

Acquired by

Halozyme Therapeutics

Founded

obfuscation

Private

Series C

Boston, Massachusetts, United States

51-100

www.elektrofi.com

Alternative Medicine

Biotechnology

Therapeutics

Funding Rounds

Series C

OBF

obfuscation

Series B

OBF

obfuscation

Grant

OBF

obfuscation

Key People

Chase Coffman: Co-founder, CEO
Victoria Sluzky: Chief Technology Officer
Past Role: BioMarin Pharmaceutical, Senior VP, Global Quality and Development

Details

Legal Name

Elektrofi, Inc.

Operating Status

Active

Company Type

For Profit

Founders

Chase Coffman

About the Company

Elektrofi develops biologic therapies through its hyper concentration microparticle platform technology, Hypercon. The company focuses on reengineering medicine delivery to support partners and patients with smarter administration methods. Elektrofi collaborates with other biopharma companies to develop new generation medicines that can be

delivered subcutaneously.

Phone Number

866-610-2683

Contact Email

info@elektrofi.com

Predictions & Insights

Growth Insight

See this Growth Insight

Elektrofi is

Lorem

to be growing

Top Contributing Factors

Recently Raised Funding

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Growth Insight

Products & Services

Hypercon™

A microparticle platform technology that enables the development of low-volume, stable, hyper-concentrated biologic formulations for subcutaneous delivery.

Formulation Development Services

Services focused on developing subcutaneous biologic therapies in collaboration with strategic partners, including process development, formulation, analytics, and innovation.

Research & Development

Elektrofi is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series C - Elektrofi	19	obfuscated obfuscation	Novo Holdings, RA Capital Management, Royalty Pharma	Series C
obfuscated obfuscation	Series C - Elektrofi	19	obfuscated obfuscation	Novo Holdings, RA Capital Management, Royalty Pharma	Series C
obfuscated obfuscation	Series C - Elektrofi	19	obfuscated obfuscation	Novo Holdings, RA Capital Management, Royalty Pharma	Series C
obfuscated obfuscation	Series C - Elektrofi	19	obfuscated obfuscation	Novo Holdings, RA Capital Management, Royalty Pharma	Series C
obfuscated obfuscation	Series C - Elektrofi	19	obfuscated obfuscation	Novo Holdings, RA Capital Management, Royalty Pharma	Series C

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series C - Elektrofi	19	obfuscated obfuscation	Novo Holdings, RA Capital Management, Royalty Pharma	Series C
obfuscated obfuscation	Series C - Elektrofi	19	obfuscated obfuscation	Novo Holdings, RA Capital Management, Royalty Pharma	Series C
obfuscated obfuscation	Series C - Elektrofi	19	obfuscated obfuscation	Novo Holdings, RA Capital Management, Royalty Pharma	Series C
obfuscated obfuscation	Series C - Elektrofi	19	obfuscated obfuscation	Novo Holdings, RA Capital Management, Royalty Pharma	Series C
obfuscated obfuscation	Series C - Elektrofi	19	obfuscated obfuscation	Novo Holdings, RA Capital Management, Royalty Pharma	Series C

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Novo Holdings	Yes	Series C - Elektrofi	—
Novo Holdings	Yes	Series C - Elektrofi	—
Novo Holdings	Yes	Series C - Elektrofi	—
Novo Holdings	Yes	Series C - Elektrofi	—
Novo Holdings	Yes	Series C - Elektrofi	—